Hyperlipidemia following treatment with antipsychotic medications

American Journal of Psychiatry

Volumn 163, Issue 10, 2006, Pages 1821-1825

  Olfson, Mark ^a   Marcus, Steven C ^b   Corey Lisle, Patricia ^b   Tuomari, A V ^b   Hines, Patricia ^b   L'Italien, Gilbert J ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAID; MOOD DISORDER; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA;

EID: 33749498006     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.10.1821     Document Type: Article

References (24)

1. Domon SE, Webber JC: Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol 2001; 11:285-288
2. Nguyen M, Murphy T: Olanzapine and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry 2001; 40:133
3. Su KP, Shen WW, Huan SY: Lipid abnormalities induced by novel antipsychotic drugs. Drug Safety 2001; 24:1017-1018
4. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C: Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 1999; 156:1471-1472
5. Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21:369-374
6. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL: Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156:1270-1272
7. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities; a five-year naturalistic study. Am J Psychiatry 2000; 157:975-981
8. Meyer JM: A retrospective comparison of weight, lipid, and glucose changes between ripseridone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63:425-433
9. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63:856-865
10. Melkersson KL, Holting A-L, Brismar KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related disorders. J Clin Psychiatry 2000; 61:742-748
11. Koro CE, Fedder DO, D'Italien GJ, Weiss S. Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59:1021-1026
12. Lund BC, Perry PJ, Brooks JM, Arndt S: Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58:1172-1176
13. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels inpatients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290-296
14. Food and Drug Administration Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules. http://www.fda.gov.ohrms. dockets.ac.00.backgrd/3619b1a.pdf
15. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28:182-192
16. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo D, Jameson JL (eds): Harrison's Principles of Internal Medicine, 16th Edition. New York, McGraw-Hill, 2005, p 2294
17. Mantel-Teeuvisse AK, Kloosterman JME, Maitland-van der See AH, Klungel OH, Posius AH, de Boer A: Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety 2001; 24:443-456
18. Brown S, Birtwistie J, Poe L, Thompson C: The unhealthy life-style of people with schizophrenia. Psychol Med 1999; 29:697-701
19. Strassnig M, Brar JS, Ganguli R: Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003; 29:393-397
20. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Nyland B: Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001; 35:196-202
21. Primesta P, Poulter NR: Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321:1322-1325
22. Frontini MG, Srinivasan SR, Elkasabany A, Berenson GS: Awareness of hypertension and dyslipidemia in a semirural population of young adults: the Bogalusa heart study. Prevent Med 2003; 36:398-402
23. Stigler KA, Potenza MN, Posey DJ, McDougle CJ: Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatric Drugs 2004; 6:33-44
24. Barak Y: No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 2002; 63:117-119